{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:04:59Z","timestamp":1769504699126,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.wneu.2020.03.155","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T19:35:41Z","timestamp":1585856141000},"page":"260-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Primary Central Nervous System Lymphoma in a Patient on Adalimumab Therapy for Chronic Plaque Psoriasis"],"prefix":"10.1016","volume":"139","author":[{"given":"Riyaq Abdi","family":"Farah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Alduaij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5593-4714","authenticated-orcid":false,"given":"Carlos","family":"Ugas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2020.03.155_bib1","series-title":"HUMIRA subcutaneous injection, adalimumab subcutaneous injection [product information]","year":"2012"},{"key":"10.1016\/j.wneu.2020.03.155_bib2","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.wneu.2020.03.155_bib3","first-page":"6","article-title":"Iatrogenic immunodeficiency-associated lymphoproliferative disorders in transplant and nontransplant settings","volume":"59","author":"Kubica","year":"2016","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.wneu.2020.03.155_bib4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1023\/A:1008376412784","article-title":"Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials","volume":"11","author":"Ferreri","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2020.03.155_bib5","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"World Health Organization","year":"2017"},{"issue":"S14","key":"10.1016\/j.wneu.2020.03.155_bib6","article-title":"Characteristics, treatment and prognosis of primary central nervous system lymphoma: a single center retrospective study","volume":"69","author":"Van Mellaert","year":"2014","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.wneu.2020.03.155_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1470-2045(00)00390-9","article-title":"Primary nervous-system lymphoma","volume":"2","author":"Plotkin","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2020.03.155_bib8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.wneu.2020.03.155_bib9","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1136\/ard.2008.102103","article-title":"Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases","volume":"68","author":"Burmester","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.wneu.2020.03.155_bib10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.wneu.2020.03.155_bib11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1529-8019.2009.01258.x","article-title":"Is there truly a risk of lymphoma from biologic therapies?","volume":"22","author":"Dommasch","year":"2009","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.wneu.2020.03.155_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaad.2015.06.038","article-title":"Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis","volume":"73","author":"Menter","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.wneu.2020.03.155_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.21037\/acr.2018.12.01","article-title":"Hodgkin\u2019s lymphoma in a patient on adalimumab treatment for psoriasis","volume":"2","author":"Alballa","year":"2018","journal-title":"AME Case Rep"},{"key":"10.1016\/j.wneu.2020.03.155_bib14","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.wneu.2020.03.155_bib15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archderm.139.11.1425","article-title":"Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom","volume":"139","author":"Gelfand","year":"2003","journal-title":"Arch Dermatol"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875020306264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875020306264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:39:59Z","timestamp":1761813599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875020306264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":15,"alternative-id":["S1878875020306264"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2020.03.155","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Central Nervous System Lymphoma in a Patient on Adalimumab Therapy for Chronic Plaque Psoriasis","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2020.03.155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}